Fractalkine is an independent predictor of mortality in patients with advanced heart failure

Summary

Immunological processes are implicated in the multifactorial pathophysiology of heart failure (HF). The multifunctional chemokine fractalkine (CX3CL1) promotes the extravasation of cytotoxic lymphocytes into tissues. We aimed to assess the prognostic value of fractalkine in HF. Fractalkine plasma levels were determined in 349 patients with advanced systolic HF (median 75 years, 66% male). During a median follow-up of 4.9 years (interquartile range: 4.6–5.2), 55.9% of patients died. Fractalkine was a significant predictor of all-cause mortality (p <0.001) with a hazard ratio of 2.78 (95% confidence interval: 1.95–3.95) for the third compared to the first tertile. This association remained significant after multivariable adjustment for demographics, clinical predictive variables and N-terminal pro-B-type natriuretic peptide (NT-proBNP, p=0.008). The predictive value of fractalkine did not significantly differ between patients with ischaemic and non-ischaemic HF aetiology (p=0.79). The predictive value of fractalkine tertiles was not significantly modified by tertiles of NT-proBNP (p=0.18) but was more pronounced in the first and third tertile of NT-proBNP. Fractalkine was also an independent predictor of cardiovascular mortality (p=0.015). Fractalkine levels were significantly lower in patients on angiotensin-converting enzyme inhibitor therapy (p <0.001). In conclusion, circulating fractalkine with its pro-inflammatory and immunomodulatory effects is an independent predictor of mortality in advanced HF patients. Fractalkine improves risk prediction beyond NTproBNP and might therefore help to identify high risk patients who need special care. Our data indicate the implication of immune modulation in HF pathology.

Keywords

Fractalkine - chemokine - heart failure - immunology - prognosis

• References

• 1 Anker SD, Coats AJ. Metabolic, functional, and haemodynamic staging for CHF?. Lancet 1996; 348: 1530-1531.
• 2 Hunt SA, Abraham WT, Chin MH. et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-479.
• 3 Beohar N, Rapp J, Pandya S, Losordo DW. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol 2010; 56: 1287-1297.
• 4 Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 2007; 9: 236-241.
• 5 Husberg C, Nygard S, Finsen AV. et al. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45: 261-269.
• 6 Hohensinner PJ, Rychli K, Zorn G. et al. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost 2010; 103: 435-441.
• 7 Hohensinner PJ, Niessner A, Huber K, Weyand CM, Wojta J. Inflammation and cardiac outcome. Curr Opin Infect Dis 2011; 24: 259-264.
• 8 Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-721.
• 9 Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97: 748-754.
• 10 Altin SE, Schulze PC. Fractalkine: a novel cardiac chemokine?. Cardiovasc Res 2011; 92: 361-362.
• 11 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
• 12 Xuan W, Liao Y, Chen B. et al. Detrimental effect of fractalkine on myocardial ischemia and heart failure. Cardiovasc Res 2011; 92: 385-393.
• 13 Murphy G, Caplice N, Molloy M. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology 2008; 47: 1446-1451.
• 14 Umehara H, Bloom ET, Okazaki T. et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
• 15 Yoshida T, Hanawa H, Toba K. et al. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 2005; 68: 278-288.
• 16 Escher F, Vetter R, Kuhl U, Westermann D, Schultheiss HP, Tschope C. Fractalkine in human inflammatory cardiomyopathy. Heart 2011; 97: 733-739.
• 17 Rauchhaus M, Doehner W, Francis DP. et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-3067.
• 18 Niessner A, Hohensinner PJ, Rychli K. et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 789-796.
• 19 Nanki T, Imai T, Nagasaka K. et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2878-2883.
• 20 Damas JK, Boullier A, Waehre T. et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005; 25: 2567-2572.
• 21 Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) 2009; 1: 391-405.
• 22 Ishida Y, Gao JL, Murphy PM. Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol 2008; 180: 569-579.
• 23 Odai T, Matsunawa M, Takahashi R. et al. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1158-1165.
• 24 Mann DL, McMurray JJ, Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602.
• 25 Celis R, Torre-Martinez G, Torre-Amione G. Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?. Curr Opin Cardiol 2008; 23: 254-260.
• 26 White GE, Tan TC, John AE, Whatling C, McPheat WL, Greaves DR. Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010; 85: 825-835.
• 27 Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730-737.
• 28 Ludwig A, Weber C. Transmembrane chemokines: versatile ’special agents’ in vascular inflammation. Thromb Haemost 2007; 97: 694-703.
• 29 Koziolek MJ, Vasko R, Bramlage C, Muller GA, Strutz F. The CX(3)C-chemokine fractalkine in kidney diseases. Mini Rev Med Chem 2009; 9: 1215-1228.
• 30 Koziolek MJ, Muller GA, Zapf A. et al. Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant 2010; 25: 684-698.
• 31 Oh DJ, Dursun B, He Z. et al. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 2008; 294: F264-271.
• 32 Cleland JG, Carubelli V, Castiello T, Yassin A, Pellicori P, Antony R. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev 2012; 17: 133-149.
• 33 Kikuchi Y, Ikee R, Hemmi N. et al. Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol 2004; 97: e17-25.
• 34 Ito Y, Kawachi H, Morioka Y. et al. Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int 2002; 61: 2044-2057.
• 35 Apostolakis S, Vlata Z, Vogiatzi K, Krambovitis E, Spandidos DA. Angiotensin II up-regulates CX3CR1 expression in THP-1 monocytes: impact on vascular inflammation and atherogenesis. J Thromb Thrombolysis 2010; 29: 443-448.
• 36 Zhang J, Patel JM. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med 2010; 3: 233-244.